Skip to content

Prevalence and Prognosis of Cardiac Amiloidosis in Turkey

Prevalence and Prognosis of Cardiac Amiloidosis in Turkey- Registry Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04915235
Acronym
PAPCAT
Enrollment
2087
Registered
2021-06-07
Start date
2020-09-18
Completion date
2025-12-31
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Amyloidosis

Brief summary

Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis

Interventions

BEHAVIORALAlgorithm

Algorithm

Sponsors

Turkish Society of Cardiology
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with left ventricular hypertrophy without left ventricular pressure or volume (IVS≥13mm) * Patients with left ventricular hypertrophy and hypertension or aortic stenosis without left ventricular pressure or volume (IVS\>15mm)

Exclusion criteria

* Patients with left ventricular pressure or volume except the ones with aortic stenosis and arterial hypertension * Patients with sigmoid septum and their hypertrophy limited in sigmoid area * Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV morhpology and genetic testing

Design outcomes

Primary

MeasureTime frameDescription
Cardiac AmyloidosisUpon screeningPatients with left ventricular hypertrophy and Cardiac Amyloidosis

Countries

Turkey (Türkiye)

Contacts

Primary ContactIlkay Gucuk, MD
tkd@tkd.org.tr902122211738

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026